Silence Therapeutics Plc (SLNCF)
4.00
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Silence Therapeutics Net Income (Quarterly) : -12.27M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -12.27M |
| March 31, 2026 | -14.96M |
| December 31, 2025 | -11.77M |
| September 30, 2025 | -20.96M |
| June 30, 2025 | -27.35M |
| March 31, 2025 | -28.53M |
| September 30, 2024 | -35.12M |
| June 30, 2024 | -19.64M |
| March 31, 2024 | -2.312M |
| Date | Value |
|---|---|
| December 31, 2023 | -17.88M |
| September 30, 2023 | -10.44M |
| June 30, 2023 | -13.02M |
| March 31, 2023 | -12.40M |
| December 31, 2022 | -16.14M |
| September 30, 2022 | -8.350M |
| June 30, 2022 | -14.98M |
| March 31, 2022 | -10.30M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | -4.134M |
| Mereo BioPharma Group Plc | -7.018M |
| Compass Pathways Plc | -254.25M |
| HemoGenyx Pharmaceuticals Plc | -- |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 12.27M |
| EPS Diluted (Quarterly) | -0.0866 |
| Enterprise Value | 495.01M |
| Earnings Yield | -10.58% |
| Normalized Earnings Yield | -10.58 |